Publications

  • Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. 
    Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N.
    Leukemia. 2018 Dec 20. doi: 10.1038/s41375-018-0302-y. [Epub ahead of print] PubMed PMID: 30573777.

  • Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide? 
    Sockel K, Platzbecker U.
    Drugs. 2018 Dec;78(18):1873-1885. doi: 10.1007/s40265-018-1011-6. PubMed PMID: 30467725.

  • Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. 
    Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.
    Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470 2045(18)30580-1. Epub 2018 Nov 12. PubMed PMID: 30442503.

  • A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. 
    Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, Guillaume T, Le Bourgeois A, Debord C, Godon C, Le Bris Y, Theisen O, Kroschinsky F, Moreau P, Béné MC, Platzbecker U, Eveillard M.
    Br J Haematol. 2018 Dec;183(5):736-746. doi: 10.1111/bjh.15626. Epub 2018 Nov 8. PubMed PMID: 30406952.

  • Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. 
    Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres M, Steensma DP, Gloaguen S.
    Blood. 2018 Nov 7. pii: blood-2018-06-857102. doi: 10.1182/blood-2018-06-857102. [Epub ahead of print] PubMed PMID: 30404811.

  • Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. 
    Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U; SUPPORT study investigators.
    Blood. 2018 Dec 20;132(25):2629-2638. doi: 10.1182/blood-2018-06-855221. Epub 2018 Oct 10. PubMed PMID: 30305280; PubMed Central PMCID: PMC6337824.

  • Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. 
    Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T.
    Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529. PubMed PMID: 30120104; PubMed Central PMCID: PMC6113613.

  • The IPSS-R has prognostic impact in untreated patients with MDS del(5q). 
    Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing U.
    Leuk Res. 2018 Sep;72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018 Jul 23. PubMed PMID: 30075323.

  • The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. 
    Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.
    Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414. PubMed PMID: 30037803; PubMed Central PMCID: PMC6058241.

  • A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. 
    Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U.
    Leukemia. 2018 Dec;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9. Epub 2018 Mar 30. PubMed PMID: 29895954; PubMed Central PMCID: PMC6286328.

  • Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. 
    Kubasch AS, Wehner R, Bazzurri S, Tunger A, Stasik S, Garzarolli M, Meinel J, Baretton G, Meier F, Thiede C, Schmitz M, Platzbecker U.
    Blood Adv. 2018 Jun 12;2(11):1187-1190. doi: 10.1182/bloodadvances.2017014811. PubMed PMID: 29844203; PubMed Central PMCID: PMC5998917.

  • Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. 
    Kubasch AS, Platzbecker U.
    Cancers (Basel). 2018 May 24;10(6). pii: E158. doi: 10.3390/cancers10060158. Review. PubMed PMID: 29795051; PubMed Central PMCID: PMC6025349.

  • Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. 
    Middeke JM, Kollinger F, Baldauf H, Stölzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Röllig C, Thiede C, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J.
    Biol Blood Marrow Transplant. 2018 Sep;24(9):1947-1951. doi: 10.1016/j.bbmt.2018.05.021. Epub 2018 May 21. PubMed PMID: 29793046.

  • Successful treatment of acquired hemophilia A with recombinant porcine factor VIII]. 
    Trautmann-Grill K, Tiebel O, Hölig K, Platzbecker U.
    Med Klin Intensivmed Notfmed. 2018 May 17. doi: 10.1007/s00063-018-0444-8. [Epub ahead of print] German. PubMed PMID: 29774375.

  • Management of patients with acute promyelocytic leukemia. 
    Kayser S, Schlenk RF, Platzbecker U.
    Leukemia. 2018 Jun;32(6):1277-1294. doi: 10.1038/s41375-018-0139-4. Epub 2018 Apr 24. Review. PubMed PMID: 29743722.

  • Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. 
    Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R.
    EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25. PubMed PMID: 29728305; PubMed Central PMCID: PMC6013781.

  • Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. 
    Datzmann T, Trautmann F, Tesch F, Mies A, Hofbauer LC, Platzbecker U, Schmitt J.
    Leuk Res. 2018 Jun;69:81-86. doi: 10.1016/j.leukres.2018.04.010. Epub 2018 Apr 21. PubMed PMID: 29705535.

  • Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. 
    Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stölzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhäuser M, Wolf D, Theurl I, Platzbecker U.
    Lancet Haematol. 2018 May;5(5):e201-e210. doi: 10.1016/S2352-3026(18)30036-X. Epub 2018 Apr 5. PubMed PMID: 29628397.

  • The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. 
    Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL, Guo S, Altincatal A, Wu C, Fenaux P.
    Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):136-144.e7. doi: 10.1016/j.clml.2017.12.004. Epub 2017 Dec 30. PubMed PMID: 29429612.

  • Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. 
    Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor- Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A.
    Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26. PubMed PMID: 29396092.

  • Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. 
    Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Löffler L, Krümpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhäuser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schäfer-Eckart K, Krämer A, Berdel WE, Serve H, Ehninger G, Schuler US; Study Alliance Leukemia (SAL).
    Ann Oncol. 2018 Apr 1;29(4):973- 978. doi: 10.1093/annonc/mdy030. PubMed PMID: 29390048.

  • An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants. 
    Stasik S, Schuster C, Ortlepp C, Platzbecker U, Bornhäuser M, Schetelig J, Ehninger G, Folprecht G, Thiede C.
    Biomol Detect Quantif. 2018 Jan 9;15:6-12. doi: 10.1016/j.bdq.2017.12.001. eCollection 2018 May. PubMed PMID: 29349042; PubMed Central PMCID: PMC5766748.

  • Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. 
    Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.
    Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20. PubMed PMID: 29275119.

  • Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. 
    Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D.
    Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11. PubMed PMID: 29241762.

  • Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. 
    Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.
    Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12. PubMed PMID: 29231969.

  • CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. 
    Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H.
    Leukemia. 2018 Apr;32(4):1049-1052. doi: 10.1038/leu.2017.346. Epub 2017 Dec 6. PubMed PMID: 29209043.

  • Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. 
    Schroeder T, Rautenberg C, Krüger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhäuser M, Kobbe G.
    Ann Hematol. 2018 Feb;97(2):335-342. doi: 10.1007/s00277-017-3185-5. Epub 2017 Nov 18. PubMed PMID: 29151133.

  • Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway. 
    Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U.
    Haematologica. 2018 Jan;103(1):61-68. doi: 10.3324/haematol.2017.172726. Epub 2017 Oct 27. PubMed PMID: 29079596; PubMed Central PMCID: PMC5777191.

  • Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. 
    Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893. [Epub ahead of print] PubMed PMID: 29963936.

  • A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. 
    Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U.
    Leukemia. 2018 Dec;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9. Epub 2018 Mar 30. PubMed PMID: 29895954; PubMed Central PMCID: PMC6286328.

  • Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. 
    Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H.
    Nat Commun. 2018 May 24;9(1):2047. doi: 10.1038/s41467-018-04384-5. PubMed PMID: 29795382; PubMed Central PMCID: PMC5967331.

  • Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
    Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P.
    Haematologica. 2018 Nov;103(11):e519- e521. doi: 10.3324/haematol.2018.193151. Epub 2018 May 24. PubMed PMID: 29794147; PubMed Central PMCID: PMC6278967.

  • NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.
    Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.
    Haematologica. 2018 Oct;103(10):e455-e457. doi: 10.3324/haematol.2018.189886. Epub 2018 May 10. PubMed PMID: 29748442; PubMed Central PMCID: PMC6165814.

  • Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. 
    Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.
    Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. PubMed PMID: 29740159.

  • Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. 
    Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.
    Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121. PubMed PMID: 29685952; PubMed Central PMCID: PMC5916007.

  • Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
    Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.
    Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9. PubMed PMID: 29649620.

  • Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. 
    Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez- Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P.
    Br J Haematol. 2018 May;181(3):350- 359. doi: 10.1111/bjh.15190. Epub 2018 Apr 2. PubMed PMID: 29611196.

  • Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. 
    Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.
    Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6. PubMed PMID: 29572506; PubMed Central PMCID: PMC5990524.

  • Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. 
    Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R.
    Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. PubMed PMID: 29535430.

  • A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. 
    List A, Ebert BL, Fenaux P. 
    Leukemia. 2018 Jul;32(7):1493-1499. doi: 10.1038/s41375-018-0029- 9. Epub 2018 Jan 30. Review. PubMed PMID: 29445113.

  • Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. 
    De Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.
    Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31. PubMed PMID: 29407183.

  • Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. 
    Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.
    Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10. PubMed PMID: 29331635.

  • Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. 
    Almeida A, Fenaux P, Garcia-Manero G, Goldberg SL, Gröpper S, Jonasova A, Vey N, Castaneda C, Zhong J, Beach CL, Santini V.
    Leuk Lymphoma. 2018 Sep;59(9):2135-2143. doi: 10.1080/10428194.2017.1421758. Epub 2018 Jan 11. PubMed PMID: 29322849.

  • Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. 
    Hilmi M, Bally C, Burns R, Lorillon G, Bergeron A, Fenaux P, Ades L.
    Ann Hematol. 2018 Mar;97(3):541-542. doi: 10.1007/s00277-017-3190-8. Epub 2017 Nov 23. PubMed PMID: 29170809.

  • A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. 
    Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, Hernandez L, Dalle JH, Sicre de Fontbrune F, Lengline E, Itzykson R, Clappier E, Boissel N, Vasquez N, Da Costa M, Masliah-Planchon J, Cuccuini W, Raimbault A, De Jaegere L, Adès L, Fenaux P, Maury S, Schmitt C, Muller M, Domenech C, Blin N, Bruno B, Pellier I, Hunault M, Blanche S, Petit A, Leverger G, Michel G, Bertrand Y, Baruchel A, Socié G, Soulier J.
    Blood. 2018 Feb 15;131(7):717-732. doi: 10.1182/blood-2017-09-806489. Epub 2017 Nov 16. PubMed PMID: 29146883.

  • Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling. 
    Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, Rousseau A, Fenaux P, Chevret S, Chapuis N, Boeva V, Fridman WH, Fontenay M, Kosmider O.
    Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3. PubMed PMID: 28972593.

  • Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). 
    Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators.
    Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24. PubMed PMID: 28838276.

  • Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies. 
    Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N; Groupe Francophone des Myélodysplasies.
    Br J Haematol. 2018 Mar;180(5):735-737. doi: 10.1111/bjh.14427. Epub 2016 Dec 15. PubMed PMID: 27977052.

  • Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related? 
    Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P.
    Br J Haematol. 2018 Jan;